Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was the target of unusually large options trading activity on Thursday. Stock traders acquired 27,192 put options on the company. This is an increase of 137% compared to the typical daily volume of 11,460 put options.
Capricor Therapeutics Stock Down 3.1%
NASDAQ CAPR traded down $0.25 during trading hours on Thursday, hitting $7.78. 4,426,090 shares of the company were exchanged, compared to its average volume of 3,242,053. The company has a 50 day moving average of $8.05 and a two-hundred day moving average of $19.65. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37. The firm has a market cap of $452.50 million, a price-to-earnings ratio of -2.97 and a beta of 0.80.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.29). On average, equities research analysts predict that Capricor Therapeutics will post -2.39 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have recently commented on CAPR shares. Maxim Group lowered Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. Cantor Fitzgerald raised shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Friday, August 14th. JonesTrading raised shares of Capricor Therapeutics from a "hold" rating to a "buy" rating and set a $25.00 target price for the company in a research note on Wednesday, November 11th. Piper Sandler upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, September 1st. Finally, HC Wainwright downgraded shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, July 27th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $30.09.
View Our Latest Analysis on Capricor Therapeutics
Hedge Funds Weigh In On Capricor Therapeutics
Several large investors have recently bought and sold shares of CAPR. KBC Group NV acquired a new position in Capricor Therapeutics during the 1st quarter worth $44,000. Activest Wealth Management increased its position in shares of Capricor Therapeutics by 100.0% in the 3rd quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 2,000 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of Capricor Therapeutics by 16.8% in the 1st quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company's stock valued at $440,000 after purchasing an additional 2,083 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Capricor Therapeutics by 21.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company's stock worth $164,000 after purchasing an additional 3,036 shares during the period. Finally, Glenmede Trust Co. NA grew its stake in shares of Capricor Therapeutics by 13.2% in the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company's stock worth $1,104,000 after purchasing an additional 4,240 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.